Blood and immune system conditions
Explore our latest news, features and CME resources on this topic, relevant to general practice.
Fostamatinib not recommended for refractory chronic immune thrombocytopenia
The cost-effectiveness estimates for fostamatinib compared with rituximab are higher than what NICE normally considers cost effective.
#VisualAbstract Brentuximab vedotin with nivolumab was well-tolerated and showed durable remissions as initial salvage therapy in relapsed/refractory classic Hodgkin's Lymphoma
Quality Evidence Briefings, Blood and immune system conditions, Cancer, Oncology, Haematological malignancies, Oncology Room
#VisualAbstract Brentuximab vedotin with nivolumab was well-tolerated and showed durable remissions as initial salvage therapy in relapsed/refractory classic Hodgkin's Lymphoma
NICE recommends first treatment for rare blood disorder
Midostaurin is reocmmended as a treatment for advanced systemic mastocytosis in adults. It the first targeted therapy for this condition to be available on the NHS.
SMC accepts treatment for primary chronic immune thrombocytopenia
Avatrombopag is accepted for restricted use within NHS Scotland.
NICE publishes new rapid guideline to diagnose and treat rare blood clotting condition associated with COVID-19 vaccination
NICE has today published a new rapid COVID-19 guideline to help healthcare staff identify and treat patients who develop the rare syndrome vaccine-induced immune thrombocytopenia and thrombosis (VITT) after receiving COVID-19 vaccinations.
Belimumab not recommended for lupus in draft guidance
Belimumab had previously been available on the NHS through a managed access agreement with NICE.
#VisualAbstract Phase 3 trial shows adding clarithromycin to standard therapy does not improve progression-free survival in patients with multiple myeloma ineligible for autologous transplant
